scPharmaceuticals Inc. (NASDAQ:SCPH) Q3 2022 Results Conference Call November 9, 2022 4:30 PM ET

Company Participants

Hans Vitzthum - IR

John Tucker - CEO

Rachael Nokes - SVP, Finance

Steve Parsons - VP, Head of Commercial

Conference Call Participants

Roanna Ruiz - SVB Securities

Glen Santangelo - Jefferies

Douglas Tsao - H.C. Wainwright

Naz Rahman - Maxim Group

Operator

Greetings, and welcome to the scPharmaceuticals Third Quarter 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Hans Vitzthum. Thank you, Mr. Vitzthum. You may begin.

Hans Vitzthum

Thank you, operator. Before turning the call over to management, I would like to make the following remarks concerning forward-looking statements. All statements on this conference call, other than historical facts, are forward-looking statements within the meaning of the federal securities laws, including, but not limited to, statements regarding scPharmaceuticals expected future financial results and management's expectations and plans for the business and FUROSCIX. The words anticipate, believe, estimate, expect, intend, guidance, confidence, target, project and other similar expressions are used typically to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and may involve and are subject to certain risks and uncertainties and other important factors that may affect scPharmaceuticals business, financial condition and other operating results.

These include, but are not limited to, the risk factors and other qualifications contained in scPharmaceuticals' annual report on Form 10-K, quarterly reports on Form 10-Q and other reports filed by the company with the SEC to which your attention is directed. Actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. Any forward-looking statements made on this conference call, including responses to your questions, are based on current expectations as of today, and scPharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. It is now my pleasure to turn the call over to Mr. John Tucker, Chief Executive Officer of scPharmaceuticals. John?

John Tucker

Thank you, Hans, and thanks to everyone listening to this afternoon's call and webcast, our first in the history of our company. I will begin with an operational overview, including a recap of recent development, and Rachael Nokes, our SVP of Finance, will follow with a brief review of our financials. The October FDA approval of FUROSCIX, the first and only self-administered subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure, represents the culmination of years of unwavering effort on behalf of the entire scPharmaceuticals team. We have successfully developed what we believe is to be a truly significant advancement in the management of heart failure. FUROSCIX offers a treatment option outside of the hospital, either pre- or post-admission. By reducing preventable hospital admissions and readmissions, we have the potential to effectively treat patients in the comfort of their own homes and potentially deliver significant cost savings for payers. Given that the benefits of FUROSCIX can accrue to multiple healthcare stakeholders, we anticipate positive uptake and are preparing for a robust commercial launch of FUROSCIX.